CVRx has appointed Tom Moore to the newly created, officer position of vice president, US Market Development. In this role, Moore will lead all field efforts related to the successful completion of the BeAT-HF (Baroreflex activation therapy for heart failure) pivotal clinical trial. Additionally, he will lead all market development activities critical to preparing the US market for a successful commercial launch after FDA approval.
A press release reports that Moore began his career at Medtronic where he held leadership roles in the areas of marketing and sales in the neuromodulation businesses. He brings 20 years of global market development experience to CVRx, and was most recently the president of a medical start-up company focused on urological disorders. Moore holds a master’s degree from The Carlson School of Management at the University of Minnesota and a bachelor’s degree in Business from the University of Colorado.
Nadim Yared, president and chief executive officer of CVRx, comments: “We are really excited to bring Tom back to CVRx in this key leadership role. Tom’s track record in leading the successful enrollment in the Rheos Pivotal Trial for the treatment of hypertension as well as the Phase II HOPE4HF feasibility study for the Barostim Neo device for the treatment of heart failure gives us further confidence in the timely enrolment of the BeAT-HF clinical trial.”
The BeAT-HF phase III clinical trial is designed to demonstrate the safety of Barostim Neo and its effectiveness on symptoms and clinical outcomes in patients suffering from chronic heart failure. The trial is intended to provide the basis for market approval in the USA.
